HM
TNGX icon

HealthCor Management’s Tango Therapeutics TNGX Stock Holding History

HealthCor Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-41,032
Closed -$456K – 104
2021
Q1 		$456K Buy
+41,032
New +$472K 0.02% 83

Other funds holding TNGX

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HealthCor Management's TNGX Position: Q2 2021 in Review

HealthCor Management sold out of Tango Therapeutics (TNGX) in Q2 2021, closing a stake of 41,032 shares — an estimated $456K sold.

HealthCor Management first reported a position in TNGX in Q1 2021 and held it in 1 quarter. The position peaked at $456K in Q1 2021. 31 funds tracked by Wall St. Rank hold TNGX as of Q2 2021.

  • HealthCor Management reported no remaining Tango Therapeutics position as of Q2 2021 after selling out during the quarter.
  • HealthCor Management sold 41,032 Tango Therapeutics shares in Q2 2021, an estimated $456K.
  • HealthCor Management first reported a position in Tango Therapeutics in Q1 2021 and held it in 1 quarter.
  • HealthCor Management's Tango Therapeutics position peaked at $456K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2021.

Based on HealthCor Management's 13F filing for Q2 2021, filed 16 Aug 2021.